To review the current literature on the use of intravitreal methotrexate (IVT MTX) for the treatment and prevention of proliferative vitreoretinopathy (PVR).
Methods:
All reports of IVT MTX to treat and prevent PVR published in PubMed, Google Scholar, and EBSCOhost were reviewed. The relevant current studies are included in this report.
Results:
The literature search yielded 32 articles describing the use of MTX in PVR. These included preclinical studies, 1 case report, and several case series. Early studies found that IVT MTX is a promising medication for the treatment and prevention of PVR. MTX works as a potent anti-inflammatory agent through a new mechanism of action different from that of other medications for use in PVR. Few side effects have been reported and were mostly limited to mild reversible corneal keratopathy. There are 2 current ongoing randomized controlled clinical trials to further evaluate the efficacy of MTX for PVR.
Conclusions:
MTX is a safe and potentially efficacious medication for the treatment and prevention of PVR. Additional clinical trials are needed to further establish this effect.
PastorJCde la RuaERMartinF.Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144. doi:10.1016/s1350-9462(01)00023-4
2.
El BahaSLeilaMAmrALolahMMA. Anatomical and functional outcomes of vitrectomy with/without intravitreal methotrexate infusion for management of proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment. J Ophthalmol. 2021;2021:3648134. doi:10.1155/2021/3648134
3.
GarwegJGTappeinerCHalberstadtM.Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 2013;58:321-329. doi:10.1016/j.survophthal.2012.12.004
4.
LeidermanYIMillerJW.Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol. 2009;24:62-69. doi:10.1016/j.survophthal.2012.12.004
5.
BennerJDDaoDButlerJWHamillKI.Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol. 2019;4:e000293. doi:10.1136/bmjophth-2019-000293
6.
CowleyMConwayBPCampochiaroPAKaiserDGaskinH.Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989;107:1147-1151. doi:10.1001/archopht.1989.01070020213027
7.
AbdiFMohammadiSSFalavarjaniKG.Intravitreal methotrexate. J Ophthalmic Vis Res. 2021;16:657-669. doi:10.1001/archopht.1989.01070020213027
8.
CronsteinBNAuneTM.Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:145-154. doi:10.1038/s41584-020-0373-9
9.
FriedmanBCronsteinB.Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301-307. doi:10.1016/j.jbspin.2018.07.004
10.
IdreesSSridharJKuriyanAE.Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin. 2019;59:221-240. doi:10.1097/IIO.0000000000000258
AhmadTRHanYStewartJM.Successful treatment of anterior segment fibrosis with intravitreal methotrexate. Am J Ophthalmol Case Rep. 2021;25:101247. doi:10.1016/j.ajoc.2021.101247
13.
SunalpMWiedemannPSorgenteNRyanSJ.Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model. Curr Eye Res. 1984;3:619-623. doi:10.3109/02713688409003063
14.
EliottDStryjewskiTP.Methotrexate for Proliferative Vitreoretinopathy. Office USPaT. Massachusetts Eye and Ear Infirmary; 2016.
15.
AmarnaniDMachuca-ParraAIWongLL, et al. Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017;58:3940-3949. doi:10.1167/iovs.16-20912
16.
NouriniaRBornaFRahimiA, et al. Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study. Ophthalmologica. 2019;242:113-117. doi:10.1159/000500271
17.
Ghasemi FalavarjaniKModarresMHadavandkhaniAKarimi MoghaddamA. Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye (Lond). 2015;29:1199-1203. https://doi-org.ezproxy1.library.arizona.edu/10.1038/eye.2015.114
18.
RocaJAYon-MendozaAHuamanNWuL.Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259:2913-2917. doi:10.1007/s00417-021-05206-z
19.
SadakaASiskRAOsherJMToygarODuncanMKRiemannCD.Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016;10:1811-1817. doi:10.2147/OPTH.S111893
20.
JahangirSJahangirTAliMHLateefQHamzaUTayyabH.Use of intravitreal methotrexate infusion in complicated retinal detachment for prevention of proliferative vitreoretinopathy in a pilot study. Cureus. 2021;13:e17439. doi:10.7759/cureus.17439
21.
SchulzARickmannAJulich-HaertelH, et al. Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. Acta Ophthalmol. 2021;99:e1070-e1076. doi:10.1111/aos.14735
22.
OzkanEBOzcanAAAlparslanN.Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. Indian J Ophthalmol. 2011;59(3):197-200. doi:10.4103/0301-4738.81026
23.
VelezGYuanPSungC, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119(10):1518-1524. doi:10.1001/archopht.119.10.1518
24.
FalavarjaniKGHadavandkhaniAParvareshMMModarresMNaseripourMAlemzadehSA.Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2020;28:513-516. doi:10.1080/09273948.2019.1597894
25.
HardwigPWPulidoJSErieJCBaratzHBuettnerH.Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol. 2006;142(5):883-885. doi:10.1016/j.ajo.2006.06.002
26.
DenstedtJSchulzDCDiaconitaVSheidowTG.Acupuncture resulting in eye penetration and proliferative vitreoretinopathy – Surgical and medical management with intraocular methotrexate. Am J Ophthalmol Case Rep. 2020;18:100605. doi:10.1016/j.ajoc.2020.100605
27.
Medicine UNLo.The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. National Institutes for Health; 2022.
28.
Medicine UNLo. Methotrexate for The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients (SIGHT). National Institutes for Health; 2021.
29.
FrenkelSHendlerKSiegalTShalomEPe’erJ.Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383-388. doi:10.1136/bjo.2007.127928
30.
ZhouXZhouXShiH, et al. Reduced frequency of intravitreal methotrexate injection lowers the risk of keratopathy in vitreoretinal lymphoma patients. BMC Ophthalmol. 2020;20:189. doi:10.1186/s12886-020-01464-3
31.
GorovoyIPrechanondTAbiaMAfsharARStewartJM.Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid. Cornea. 2013;32:1171-1173. doi:10.1097/ICO.0b013e3182910106
32.
ChoudhuryHJindalAPathengayAFlynnHWJr.An outbreak of Ralstonia pickettii endophthalmitis following intravitreal methotrexate injection. Clin Ophthalmol. 2015;9:1117-1120. doi:10.2147/OPTH.S81218
33.
SmithJRRosenbaumJTWilsonDJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716. doi:10.1016/s0161-6420(02)01125-9
34.
CharterisDGSethiCSLewisGPFisherSK.Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology. Eye. 2002;16:369-374. doi:10.1038/sj.eye.6700194
35.
HardwigPWPulidoJSBakriSJ.The safety of intraocular methotrexate in silicone-filled eyes. Retina. 2008;28:1082-1086. doi:10.1097/IAE.0b013e3181754231
36.
AnvariPFalavarjaniKG.Adjunctive pharmacological therapies in the management of proliferative vitreoretinopathy. In: SpandauUTomicZRuiz-CasasD, eds. Retinal Detachment Surgery and Proliferative Vitreoretinopathy. Springer Cham; 2018:25-33. doi:10.1007/978-3-319-78446-5_3
37.
ChenCChenPLiH.Combined 5-fluorouracil and low molecular weight heparin for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment: a meta-analysis. Font Med. 2021;8:790460. doi:10.3389/fmed.2021.790460
BanerjeePJQuartilhoABunceC, et al. Slow-release dexamethasone in proliferative vitreoretinopathy. Ophthalmology. 2017;124(6):757-767. doi:10.1016/j.ophtha.2017.01.021
40.
WickhamLBunceCWongDMcGurnDCharterisDG.Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698-704. doi:10.1016/j.ophtha.2006.08.042
41.
ZhaoXYXiaSWangEQChenYX.Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment: a meta-analysis of prospective studies. Retina. 2018;38(3):462-470. doi:10.1097/IAE.0000000000001584
42.
SunalpMAWiedemannPSorgenteNRyanSJ.Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit. Exp Eye Res. 1985;41(1):105-115. doi:10.1016/0014-4835(85)9099-5
43.
AhmadiehHFeghhiMTabatabaeiHShoeibiNRamezaniAMohebbiMR.Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115(11):1938-1943. doi:10.1016/j.ophtha.2008.05.016
44.
HouHHuffmanKRiosSFreemanWRSailorMJChengL.A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci. 2015;56:2755-2763.
45.
WiedemannPHilgersRDBauerPHeimannK.Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126(4):550-559. doi:10.1016/s0002-9394(98)00115-9
46.
Medicine UNLo. The PREVENT-PVR Trial – A Multi-Center, Randomized, Sham-Controlled, Phase II Clinical Trial Evaluating Intravitreal Aflibercept for The Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair. National Institutes for Health; 2022.
